Career Development Program

职业发展计划

• 批准号: 8754354
• 负责人: SHASHIKANT LELE
• 金额: $ 6.53万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8754354
• 关键词: Advocate; Award; Clinical; Development; Disorder by Site; Faculty; Funding; Goals; Group Meetings; Individual; Malignant neoplasm of ovary; Mentors; Nursing Faculty; Patients; Population Programs; Process; Recommendation; Research; Research Personnel; Research Training; Resources; Series; Specimen; Structure; Study Section; Target Populations; Tissues; Underrepresented Minority; United States National Institutes of Health; University of Pittsburgh Cancer Institute; anticancer research; career; career development; experience; interest; meetings; next generation; novel; population based; professor; programs

The purpose of the Career Developmental Program (CDP) of the RPCI-UPCI Ovarian Cancer SPORE is to support the career development of junior researchers in translational ovarian cancer research. The target population for the program is outstanding entry-level (i.e. Assistant Professor) scientific and clinical faculty, but in some cases may include senior postdoctoral or clinical fellows with exceptional potential for independent research careers, or established investigators wishing to refocus their careers on translational ovarian cancer research. A secondary goal of the CDP is to promote the diversity of ovarian cancer researchers, by encouraging the recruitment of outstanding individuals from underrepresented groups. The CDP will be supported both by RPCI-UPCI Ovarian Cancer SPORE funds and matching institutional funds from RPCI and UPCI. The CDP serves as a structured mechanism for identifying outstanding candidates through an open and competitive application and review process, and matching the resulting awardees with experienced mentors. The CDP Leaders will convene a NIH format study section and assign NIH R21-type applications to two scientific and one patient advocate reviewers. Review results will be summarized in the Administrative Core and submitted to the Internal Advisory Board for recommendations for funding. Successful applications will be funded at the level of $50,000 per year for of two years (total award $100,000). We anticipate to fund three to five awards per year depending on the funding year. CDP awardees will be provided full access to the RPCI-UPCI Ovarian Cancer SPORE Core resources, including tissue specimens and statistical support. The CDP will directly facilitate career development through: i) a constructive proposal review by the RPCI-UPCI Ovarian Cancer SPORE Executive Committee and Internal Advisory Board, which are composed of talented investigators with expertise in basic, clinical, and population-based research, ii) research training with a mentor chosen from among a diverse faculty with broad expertise in academic career development, and iii) access to development/enrichment programs, including ovarian cancer disease site research group meetings, periodic SPORE meetings, seminar series, and RPCI-UPCI Ovarian Cancer SPORE annual retreats. In summary, the CDP provides a vital mechanism for the development of the next generation of translational ovarian cancer researchers at RPCI and UPCI.

RPCI-UPCI 卵巢癌 SPORE 职业发展计划 (CDP) 的目的是支持转化性卵巢癌研究的初级研究人员的职业发展。该计划的目标人群是杰出的入门级（即助理教授）科学和临床教师，但在某些情况下可能包括具有独立研究职业潜力的高级博士后或临床研究员，或希望将其职业重新集中在转化卵巢癌研究上的知名研究人员。 CDP 的第二个目标是通过鼓励从代表性不足的群体中招募杰出人士来促进卵巢癌研究人员的多样性。 CDP 将得到 RPCI-UPCI 卵巢癌 SPORE 基金以及来自 RPCI 和 UPCI 的配套机构基金的支持。 CDP 是一种结构化机制，通过公开且竞争性的申请和审核流程来识别优秀候选人，并将最终获奖者与经验丰富的导师进行匹配。 CDP 领导人将召开 NIH 形式的研究小组，并将 NIH R21 类型的申请分配给两名科学和一名患者倡导审查员。审查结果将在行政核心中进行总结，并提交给内部咨询委员会以获得资助建议。成功的申请将获得为期两年的每年 50,000 美元的资助（总奖金 100,000 美元）。根据资助年份，我们预计每年资助三到五个奖项。 CDP 获奖者将能够完全访问 RPCI-UPCI 卵巢癌 SPORE 核心资源，包括组织标本和统计支持。 CDP 将通过以下方式直接促进职业发展：i) 由 RPCI-UPCI 卵巢癌 SPORE 执行委员会和内部咨询委员会进行建设性提案审查，该委员会由具有基础、临床和人群研究专业知识的优秀研究人员组成，ii) 从在学术职业发展方面具有广泛专业知识的多元化教师中选出的导师进行研究培训，以及 iii) 参与发展/丰富计划，包括卵巢癌疾病现场研究小组会议， 定期 SPORE 会议、研讨会系列以及 RPCI-UPCI 卵巢癌 SPORE 年度静修会。总之，CDP 为 RPCI 和 UPCI 下一代转化性卵巢癌研究人员的发展提供了重要机制。